Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Jul
23
Today In Oncology
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
Multiple Myeloma Studies Highlight Advances Across the Field
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?
Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo